---
schema_version: "secwatch.filing_event.v1"
accession: "0000037785-26-000139"
form_type: "8-K"
ticker: "FMC"
cik: "0000037785"
company_name: "FMC CORP"
filed_at: "2026-07-29T20:44:06+00:00"
generated_at: "2026-07-29T20:45:07.231121+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# FMC Q2 revenue down 17% to $867M, GAAP loss $1.49/share; lowers full-year guidance

## Summary
- Q2 revenue $867M (-17% YoY); GAAP net loss $187M ($1.49 loss per share); adjusted EPS $0.26 (-62%).
- Adjusted EBITDA $153M (-26% YoY); cash from ops $363M including $200M rimisoxafen licensing payment.
- Full-year 2026 outlook lowered: revenue ex-India $3.50B-$3.70B, Adj. EBITDA $620M-$680M, Adj. EPS $1.19-$1.49.
- Strategic actions: India sale ($252M), rimisoxafen licensing ($200M), Newark sale-leaseback ($114M), Tessenderlo equity ($400M) – ~$1B for debt reduction.
- Board concludes strategic review; Q3 Adj. EBITDA guided $120M-$140M, Q4 $275M-$315M.

## SEC filing metadata
- accession: 0000037785-26-000139
- form_type: 8-K
- ticker: FMC
- cik: 0000037785
- company_name: FMC CORP
- filed_at: 2026-07-29T20:44:06+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/37785/000003778526000139/0000037785-26-000139-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/37785/000003778526000139/fmc-20260729.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000037785-26-000139
- JSON: https://secwatch.observer/filing/0000037785-26-000139.json
- Plain text: https://secwatch.observer/filing/0000037785-26-000139.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.